RNAZ_OUT_1 [2025-03-21 08:07:00 -0400] 2178 Bytes | 572 tokens | Cum: 572 tkns (7.15% of 8k)
==========================================================================

Listen up, partner—it's 8:06:59 AM on Fri Mar 21, 2025 -0400, and I’m revved up about TransCode Therapeutics (RNAZ), climbing from 0.77 to 0.9903. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

Here's the first list of news for TransCode Therapeutics:

C1 - Mar-14-25 08:35AM - SRC approves opening of TransCodes fourth cohort in trial of TTX-MC138
C2 - Mar-13-25 07:47AM - TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial
C3 - Feb-25-25 04:15PM - TransCode Therapeutics, Inc. Announces Results of Special Meeting
C4 - Feb-06-25 08:00AM - TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
C5 - Feb-04-25 04:15PM - TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
C6 - Jan-14-25 08:00AM - TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial
C7 - Jan-07-25 08:00AM - Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
C8 - Dec-18-24 08:00AM - TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on TransCode Therapeutics (RNAZ)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

RNAZ_OUT_3 [2025-03-21 08:07:12 -0400] 1040 Bytes | 256 tokens | Cum: 830 tkns (10.38% of 8k)
==========================================================================

Showing C1 (chunk 1 of 4): C1:
**SRC approves opening of TransCodes fourth cohort in trial of TTX-MC138**
Date: Mar-14-25 08:35AM
Source: (Clinical Trials Arena)
URL: https://finance.yahoo.com/m/6170f186-6e1a-3e7f-bd90-acdca6c38700/src-approves-opening-of.html

A US Safety Review Committee (SRC) has granted unanimous approval for TransCode Therapeutics to open the fourth cohort in its Phase I trial of TTX-MC138 for treating several metastatic cancers.

This decision follows the committee’s 'favourable' safety data review of cohort three.

Subjects in the fourth cohort will receive a dose nearly 50% higher than the previous cohort, adhering to the original clinical protocol.

They will continue in the study, provided there are no safety concerns or disease progression.

Out of nine therapy-treated subjects, six remain under treatment, with the longest-standing subject having received seven doses nearly 28 days apar

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

RNAZ_OUT_5 [2025-03-21 08:07:13 -0400] 1038 Bytes | 223 tokens | Cum: 1313 tkns (16.41% of 8k)
==========================================================================

Showing C1 (chunk 2 of 4): t for more than seven months.

The Phase I multicentre trial involves dose-escalation and dose-expansion stages for generating data on the tolerability and safety of TTX-MC138 in patients with various metastatic solid cancers.

Although not an endpoint, the trial may also offer preliminary evidence of the clinical activity of the therapy.

The initial dose-escalation stage aims to assess the tolerability and safety of increasing therapy doses while the subsequent dose-expansion stage will further evaluate its tolerability, anti-tumour activity and safety in selected tumour types, based on the dose-escalation outcomes.

The SRC has also granted approval for the enrolment of more subjects in cohort three to enhance the safety profile of the therapy.

Analysis of data from the first two cohorts for pharmacodynamic (PD) and pharmacokinetic (PK) activity is under way, indicating that the ther

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

RNAZ_OUT_7 [2025-03-21 08:07:14 -0400] 1044 Bytes | 239 tokens | Cum: 1554 tkns (19.43% of 8k)
==========================================================================

Showing C1 (chunk 3 of 4): apy exhibits a PK/PD profile in line with preclinical findings and outcomes from the company’s Phase 0 trial.

The therapy is said to target microRNA-10b, which is said to contribute to metastatic disease progression.

TransCode Therapeutics Operations senior vice-president Sue Duggan said: "SRC approval to open the fourth cohort and expand enrolment in Cohort 3 is an important advancement for the clinical trial. It will provide an opportunity to obtain additional safety and PK/PD data, inform the dose expansion stage of the clinical trial, and may allow us to obtain initial evidence of clinical activity.”

In August 2023, TransCodedosed the first subjectin the Phase 0 trial of TTX-MC138 for treating advanced solid tumours.

"SRC approves opening of TransCode’s fourth cohort in trial of TTX-MC138" was originally created and published byClinical Trials Arena, a GlobalData owned brand.

Th

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

RNAZ_OUT_9 [2025-03-21 08:07:16 -0400] 990 Bytes | 289 tokens | Cum: 1845 tkns (23.06% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-14T09:18:00Z - Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Applied Opto...
A2 - 2025-03-13T17:20:27Z - 12 Health Care Stocks Moving In Thursday's Intraday Session - Aveanna Healthcare Hldgs (NASDAQ:AVAH)...
A3 - 2025-03-13T13:25:05Z - Pre-market Movers: YMAB, AVAH, PATH, Exicure, CCLD....
A4 - 2025-03-13T12:45:02Z - TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/I...
A5 - 2025-03-13T12:00:05Z - TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/I...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

RNAZ_OUT_11 [2025-03-21 08:07:17 -0400] 1038 Bytes | 284 tokens | Cum: 2131 tkns (26.64% of 8k)
==========================================================================

Showing A1 (chunk 1 of 6): A1:
**Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Applied Optoelectronics (NASDAQ:AAOI), Bit Origin (NASDAQ:BTOG)**Date: 2025-03-14Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/25/03/44323797/why-rubrik-shares-are-trading-higher-by-over-20-here-are-20-stocks-moving-premarketShares of Rubrik, Inc. RBRK rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quarter guidance above estimates.

Rubrik reported quarterly losses of 61 cents per share, which beat the analyst consensus estimate for losses of 80 cents. Quarterly revenue clocked in at $258.1 million, which beat the analyst consensus estimate of $233.1 million.

Rubrik shares climbed 20.8% to $66.84 in the pre-market trading session.

Here are some o

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

RNAZ_OUT_13 [2025-03-21 08:07:19 -0400] 915 Bytes | 281 tokens | Cum: 2414 tkns (30.18% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-07-23T17:26:37Z - Why Transcode Therapeutics (RNAZ) Stock Is Down 60% - Benzinga
B2 - 2024-06-10T12:07:00Z - Beat the Market Like Zacks: Goldman Sachs, Micron, Amgen in Focus
B3 - 2024-06-10T11:00:00Z - Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
B4 - 2024-05-29T13:15:00Z - TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
B5 - 2024-05-12T10:18:00Z - Successful Penny Stocks Trader Tips, 3 To Use
B6 - 2024-04-03T13:10:00Z - TransCode Therapeutics Reports 2023 Results; Provides Business Update

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

RNAZ_OUT_15 [2025-03-21 08:07:22 -0400] 646 Bytes | 173 tokens | Cum: 2589 tkns (32.36% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Why Transcode Therapeutics (RNAZ) Stock Is Down 60% - Benzinga**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/24/07/39913968/why-transcode-therapeutics-rnaz-stock-is-down-60Transcode Therapeutics (RNAZ) stock is trading 62% lower after the company announced the pricing of a public offering of 10 million shares at $0.30 per share, aiming to raise $3 million. The funds will be used for product development, including clinical trials for their lead therapeutic candidate.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

RNAZ_OUT_17 [2025-03-21 08:07:23 -0400] 812 Bytes | 231 tokens | Cum: 2880 tkns (36.00% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2024-12-02 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On November 26, 2024, TransCode Therapeutics, Inc. (the Company ) entered into a securities purchase agreement (the Purchase Agrmt ) with certain accredited investors, pursuant to which the Company agreed to sell and iss...

S2 - 2024-11-14 10-Q PART I. FIN INFO

ITEM 1. FIN STATEMENTS

TRANSCODE THERAPEUTICS, INC.

BAL SHEETS

September 30,

December 31,

(Unaudited)

Assets

Curr assets:

Cash

$

1,875,862

$

2,767,598

Grant receivable

11,953

Prepaid expenses and other current a...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

RNAZ_OUT_19 [2025-03-21 08:07:25 -0400] 1038 Bytes | 269 tokens | Cum: 3151 tkns (39.39% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 1.01 Entry into a Material Definitive Agreement.

On November 26, 2024, TransCode Therapeutics, Inc. (the Company ) entered into a securities purchase agreement (the Purchase Agreement ) with certain accredited investors, pursuant to which the Company agreed to sell and issue in a private placement (the Private Placement ) an aggregate of (i) 5,710,000 shares (the Shares ) of common stock of the Company ( Common Stock ), par value $0.0001 per share, (ii) 15,510,160 pre-funded warrants to purchase shares of Common Stock (the Pre-Funded Warrants ) (iii) 21,220,160 Series C Warrants to purchase shares of Common Stock (the Series C Warrants ) and (iv) 21,220,160 Series D Warrants to purchase shares of Common Stock (the Series D Warrants and together with the Series C Warrants, the Common Warrants ; the Common Warrants together with the Pre-Funded Warrants, the Warrants ; the Warran

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

RNAZ_OUT_21 [2025-03-21 08:07:32 -0400] 1038 Bytes | 238 tokens | Cum: 3391 tkns (42.39% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): ts together with Shares, the Purchased Securities ). Each Share or Pre-Funded Warrant, as applicable, was sold together with one Series C Warrant to purchase one share of Common Stock and one Series D Warrant to purchase one share of Common Stock. The price for each Share and accompanying Common Warrants was $0.377, and the price for each Pre-Funded Warrant and accompanying Common Warrants was $0.3769 (the Offering Price).

The Pre-Funded Warrants have an exercise price of $0.0001 per share, are exercisable immediately and expire when exercised in full. Each Series C Warrant has an initial exercise price per share of $0.475 and will be exercisable beginning on the date on which Stockholder Approval (as defined below) is received and deemed effective (the Initial Exercise Date or the Stockholder Approval Date ). The Series C Warrants will expire on the five-year anniversary of the Initial

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

RNAZ_OUT_23 [2025-03-21 08:07:45 -0400] 4265 Bytes | 1217 tokens | Cum: 4741 tkns (59.26% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+----------------------+------------------------+----------------------+--------------------------+
| Volume: 1,919,044 | SMA50: -85.15% | Market Cap: 0.54M | Option/Short: No / Yes | Sales past 5Y: 0.00% | Sales Surprise: -100.00% |
+-------------------+-----------------------+----------------------+------------------------+----------------------+--------------------------+
| Avg Volume: 2.61M | SMA200: -94.43% | Shs Outstand: 0.70M | Short Float: 81.96% | Employees: 10 | EPS Surprise: 67.35% |
+-------------------+-----------------------+----------------------+------------------------+----------------------+--------------------------+
| Rel Volume: 0.71 | Perf Week: 3.77% | Shs Float: 0.66M | Short Ratio: 0.21 | Debt/Eq: 0.09 | P/E: - |
+-------------------+-----------------------+----------------------+------------------------+----------------------+--------------------------+
| RSI (14): 26.61 | Perf Month: -92.19% | Inst Own: 26.18% | Short Interest: 0.54M | Sales Y/Y TTM: - | Earnings: Nov 11 |
+-------------------+-----------------------+----------------------+------------------------+----------------------+--------------------------+
| ATR (14): 0.78 | Perf Quarter: -88.56% | Insider Own: 5.08% | Beta: 1.40 | ROE: -490.03% | |
+-------------------+-----------------------+----------------------+------------------------+----------------------+--------------------------+
| SMA20: -65.02% | Index: - | Insider Trans: 0.00% | Sales Q/Q: - | ROI: -903.45% | |
+-------------------+-----------------------+----------------------+------------------------+----------------------+--------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: TransCode Therapeutics, Inc. Common Stock
Market Cap: N/A
Shares Outstanding: N/A
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -5190814.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.77
Average Volume: 2465721.55
30-Day High: 9.86
30-Day Low: 0.742

[Detailed Financials: Q2 2024]
- Total Assets: $4,824,588.0
- Total Liabilities: $3,502,314.0
- Total Equity: $1,322,274.0
- Current Assets: $4,386,421.0
- Current Liabilities: $3,502,314.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: $-5,190,814.0
- Operating Income: $-5,113,916.0
- Earnings Per Share (EPS): -0.74

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-1,559,125.0

[Detailed Financials: Q1 2024]
- Total Assets: $7,290,467.0
- Total Liabilities: $2,706,172.0
- Total Equity: $4,584,295.0
- Current Assets: $6,714,022.0
- Current Liabilities: $2,706,172.0

[Income Statement: Q1 2024]
- Revenue: $0.00
- Net Income: $-3,326,812.0
- Operating Income: $-3,288,982.0
- Earnings Per Share (EPS): -0.65

[Cash Flow Statement: Q1 2024]
- Net Cash Flow: $2,146,078.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

RNAZ_OUT_25 [2025-03-21 08:07:47 -0400] 676 Bytes | 167 tokens | Cum: 5117 tkns (63.96% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

RNAZ_IN_27 [2025-03-21 08:07:48 -0400] 126 Bytes | 29 tokens | Cum: 5174 tkns (64.68% of 8k)
==========================================================================

====================================
[2025-03-21 05:07:48] # Analysis Completed
Elapsed Time: 49.85 seconds